ClinicalTrials.gg

Program

GS1-144

Also written as “GS1-144 tablet”, “GS1-144 tablets” and “[14C]GS1-144”.

Its studies are led by Changchun GeneScience Pharmaceutical.

Furthest: phase 2, since Dec 5, 20246 company-led studies, 2 open or runningNext primary completion: Jan 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Changchun GeneScience Pharmaceutical62 open or runningphase 2since Dec 5, 2024Jan 3, 2024Jan 31, 2027phase 1 · NCT07491289

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 3, 2024First study: phase 1 study in Vasomotor SymptomsFirst studyNCT06204250 · 86 enrolled · Australia
  2. Apr 11, 2024Phase 1 study in Vasomotor System; LabileNCT06385158 · 110 enrolled · China
  3. Dec 5, 2024Phase 2 study in Vasomotor SyndromeNCT06726850 · 129 enrolled · China
  4. Mar 18, 20262 phase 1 studiesNCT07491289, NCT07534176
  5. Apr 7, 2026Phase 1 study in Healthy Postmenopausal WomenNCT07537231 · 6 enrolled · China

Ahead

  1. Jan 31, 2027Primary completion: phase 1 study in Hepatic Impairment and Healthy FemaleNCT07491289

TargetBeta

TACR3 →read by rule
“GS1-144 tablet is an NK3R antagonist.”study text, by rule · the study

Other programs on TACR3

ProgramCompanyFurthest phaseStudies
elinzanetantruleBayerphase 324
fezolinetantruleAstellas Pharmaphase 321

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07537231Healthy Postmenopausal Women · China1Active, not recruitingApr 18, 20266
NCT07534176Postmenopause · China1CompletedJul 2, 202624
NCT07491289Hepatic Impairment and Healthy Female · China1Not yet recruitingJan 31, 202724
NCT06726850Vasomotor Syndrome · China2CompletedApr 17, 2025129
NCT06385158Vasomotor System; Labile · China1CompletedJan 6, 2024110
NCT06204250Vasomotor Symptoms · Australia1CompletedDec 19, 202486

How it is read

Names in the registry

  • “GS1-144”, 2 entries
  • “GS1-144 tablet”, 2 entries
  • “GS1-144 tablets”, 1 entry
  • “[14C]GS1-144”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.